Health Condition 1: N003- Acute nephritic syndrome with diffuse mesangial proliferative glomerulonephritis Health Condition 2: N005- Acute nephritic syndrome with diffuse mesangiocapillary glomerulonephritis Health Condition 3: N001- Acute nephritic syndrome with focal and segmental glomerular lesions Health Condition 4: N042- Nephrotic syndrome with diffuse membranous glomerulonephritis Health Condition 5: N045- Nephrotic syndrome with diffuse mesangiocapillary glomerulonephritis Health Conditi
Conditions
Interventions
Intervention1: Losartan plus Enalapril: Primary glomerular disease patient who have received Tablet Losartan 100mg per day for atleast 4 weeks will be given Tablet Enalapril which will be uptitrated t
Sponsors
Department of Nephrology
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients with primary glomerular diseases â?? MN, FSGS, IgAn, iMPGN, MCD 2. Patients with who have received single RAAS blocking agent (LOSARTAN 100 mg) for atleast 4 weeks and having proteinuria more than 500 mg/day 3. Age >12 years 4. Either sex
Exclusion criteria
Exclusion criteria: 1. Secondary glomerulonephritis. 2. Prior history of angioedema 3. Bilateral renal artery stenosis 4. Pregnancy 5. Serum Potassium more than 5.1 mmol/L 6. eGFR < 30 ml/min
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the incidence and severity of adverse event related to RAAS inhibition in patients with primary glomerular diseasesTimepoint: 1 year | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To study the decrease in proteinuria at the end of 1styear post randomization 2. To study the reduction in decline in eGFR at the end of 1styear post randomization 3. To study the incidence of other adverse events related to ACEI (dry cough, angioedema)Timepoint: 1 year | — |
Countries
India
Contacts
Public ContactDr Tukaram Jamale
Seth GSMC and KEM hospital Mumbai
Outcome results
None listed